Vimian Group AB Q2 2026 Results
Vimian Group AB, the Swedish veterinary and animal‑health company, reported second‑quarter 2026 financials that surpassed analyst expectations. Revenue was 4 % higher than the company‑compiled consensus, achieving organic growth of 12 % compared with the consensus forecast of 9.2 %. Adjusted EBITA also outperformed estimates by 4 %.
The Medtech division recorded 11 % organic growth, driven by double‑digit expansion in both the Orthopaedics and Dental segments. The North America Medtech business returned to low single‑digit organic growth, aligning with the company’s expectations.
Specialty Pharma delivered 14 % organic growth; when the impact of a U.S. sales campaign is excluded, organic growth was 9 %. The Diagnostics segment posted 7 % organic growth against a consensus of 5.6 %, but its margin fell to 9 % versus the consensus estimate of 10.1 %.
Veterinary Services grew 10 % versus the expected 10.9 % and achieved a margin of 28.2 %, slightly above the consensus margin of 27.7 %.
Following the release, Vimian Group AB shares rose approximately 2.3 % (reported as 2.61 % in some feeds) after recovering from intraday lows.